Skip to main content
Erschienen in: Clinical and Translational Oncology 12/2019

03.04.2019 | Research Article

Are there enough radiation oncologists to lead the new Spanish radiotherapy?

verfasst von: A. Rodríguez, M. Arenas, P. C. Lara, J. López-Torrecilla, M. Algara, A. Conde, H. Pérez-Montero, J. L. Muñoz, P. Peleteiro, M. J. Pérez-Calatayud, J. Contreras, C. Ferrer, The Spanish Society of Oncology and Radiotherapy (SEOR) Analysis Group

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Aim

Radiation oncology services in Spain are undergoing a process of technical modernization, but—in a context of increasing demand by an ageing population—it is unclear whether there are enough radiation oncologists to staff the newly equipped units. This study aims to assess the number of specialists working in radiation oncology services in Spain relative to current and future needs.

Materials and methods

In the second half of 2017, the Commission on Infrastructures of the Spanish Society for Radiation Oncology (SEOR) sent a questionnaire on radiation oncology staff to the heads of all 122 public (n = 76, 62%) and private (n = 46, 38%) radiation oncology services in Spain. Data collected were the number of professionals, their position, and their year of birth for specialists and residents in each service. In the descriptive analysis, for continuous variables we calculated means, standard deviations and ranges for each Spanish region and work post. For qualitative variables, we constructed frequency tables. All analyses were performed with R statistical software, version 3.5.1.

Results

The survey response rate was 100% among service heads across all 122 centers. The total number of radiation oncologists working in these centers is 721, or 15.4 per million population, with considerable variations between regions. Given the national recommendations to have 20 radiation oncologists per million population, there is currently a deficit of 204 specialists. If the 163 upcoming retirements are also taken into account, there will be 367 fewer radiation oncologists than required to meet the 25% increase in indications for radiotherapy projected for 2025.

Conclusions

The classic model for calculating staff needs based on the number of treatments is outdated, and recommendations should be revised to reflect the current reality. A new model should integrate the most complex technological advances and emerging plans in radiotherapy, without neglecting the other activities carried out in radiation oncology services that are not directly linked to patient care.
Literatur
1.
Zurück zum Zitat Rodríguez A, Borràs JM, López-Torrecilla JL, Algara M, Palacios-Eito A, Gómez-Caamaño A, et al. Demand for radiotherapy in Spain. Clin Transl Oncol. 2017;19(2):204–10.CrossRef Rodríguez A, Borràs JM, López-Torrecilla JL, Algara M, Palacios-Eito A, Gómez-Caamaño A, et al. Demand for radiotherapy in Spain. Clin Transl Oncol. 2017;19(2):204–10.CrossRef
3.
Zurück zum Zitat Borràs JM, Lievens Y, Barton M, Corral J, Ferlay J, Bray F, et al. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiother Oncol. 2016;119(1):5–11.CrossRef Borràs JM, Lievens Y, Barton M, Corral J, Ferlay J, Bray F, et al. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiother Oncol. 2016;119(1):5–11.CrossRef
4.
Zurück zum Zitat Rodríguez A, Algara M, Monge D, López-Torrecilla J, Caballero F, Morera R, et al. Infrastructure and equipment for radiation oncology in the Spanish National Health System: analysis of external beam radiotherapy 2015–2020. Clin Trans Oncol. 2018;20(3):402–10.CrossRef Rodríguez A, Algara M, Monge D, López-Torrecilla J, Caballero F, Morera R, et al. Infrastructure and equipment for radiation oncology in the Spanish National Health System: analysis of external beam radiotherapy 2015–2020. Clin Trans Oncol. 2018;20(3):402–10.CrossRef
5.
Zurück zum Zitat Arenas M, Sabater S, Gascón M, Henriquez I, Bueno MJ, Rius A, et al. Quality assurance in radiotherapy: analysis of the causes of not starting on early radiotherapy withdrawal. Radiat Oncol. 2014;4(9):260.CrossRef Arenas M, Sabater S, Gascón M, Henriquez I, Bueno MJ, Rius A, et al. Quality assurance in radiotherapy: analysis of the causes of not starting on early radiotherapy withdrawal. Radiat Oncol. 2014;4(9):260.CrossRef
6.
Zurück zum Zitat Lara PC, Rodriguez A, Ferrer C, Aristu JJ, Prada PJ, Muñoz J, et al. Rescuing Spanish radiation therapy: the role of leadership and opportunity. Int J Radiat Oncol Biol Phys. 2018;100(2):292–6.CrossRef Lara PC, Rodriguez A, Ferrer C, Aristu JJ, Prada PJ, Muñoz J, et al. Rescuing Spanish radiation therapy: the role of leadership and opportunity. Int J Radiat Oncol Biol Phys. 2018;100(2):292–6.CrossRef
7.
Zurück zum Zitat Amalia PE, Sonia GC, Ismael HC, José ASC, María EC, María M-P. Análisis de situación y estrategias de futuro. Recursos Humanos en Oncología Radioterápica. Cap 4.1 en Libro Blanco SEOR XXI. 2010;53–63. ISBN 978-84-7714-344-4. Amalia PE, Sonia GC, Ismael HC, José ASC, María EC, María M-P. Análisis de situación y estrategias de futuro. Recursos Humanos en Oncología Radioterápica. Cap 4.1 en Libro Blanco SEOR XXI. 2010;53–63. ISBN 978-84-7714-344-4.
8.
Zurück zum Zitat Esco R, Palacios A, Pardo J, Biete A, Carceller JA, Veiras C, et al. Infrastructure of radiotherapy in Spain: a minimal standard of radiotherapy resources. Int J Radiat Oncol Biol Phys. 2003;56(2):319–27.CrossRef Esco R, Palacios A, Pardo J, Biete A, Carceller JA, Veiras C, et al. Infrastructure of radiotherapy in Spain: a minimal standard of radiotherapy resources. Int J Radiat Oncol Biol Phys. 2003;56(2):319–27.CrossRef
9.
Zurück zum Zitat Palacios A, Espinosa M, Mañas A, de las Heras M. Radiation oncology: future needs and equipment. Current situation in Spain. Clin Trans Oncol. 2008;10:478–85.CrossRef Palacios A, Espinosa M, Mañas A, de las Heras M. Radiation oncology: future needs and equipment. Current situation in Spain. Clin Trans Oncol. 2008;10:478–85.CrossRef
10.
Zurück zum Zitat Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol. 2005;75(3):355–65.CrossRef Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol. 2005;75(3):355–65.CrossRef
11.
Zurück zum Zitat Slotman BJ, Cottier B, Bentzen SM, Heeren G, Lievens Y, Van den Bogaert W. Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol. 2005;75(3):349–54.CrossRef Slotman BJ, Cottier B, Bentzen SM, Heeren G, Lievens Y, Van den Bogaert W. Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol. 2005;75(3):349–54.CrossRef
12.
Zurück zum Zitat Grau C, Dofourney N, Malicki J, Dunscombe P, Borras JM, Coffey M, et al. Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112:155–64.CrossRef Grau C, Dofourney N, Malicki J, Dunscombe P, Borras JM, Coffey M, et al. Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112:155–64.CrossRef
13.
Zurück zum Zitat Lievens Y, Defourny N, Coffey M, Borras JM, Dunscombe P, Slotman B, et al. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112:178–86.CrossRef Lievens Y, Defourny N, Coffey M, Borras JM, Dunscombe P, Slotman B, et al. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112:178–86.CrossRef
14.
Zurück zum Zitat Rosenblatt E, Izewska J, Anacak Y, Pynda Y, Scaillet P, Boniol M. Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database. Lancet Oncol. 2013;14(2):e79–86.CrossRef Rosenblatt E, Izewska J, Anacak Y, Pynda Y, Scaillet P, Boniol M. Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database. Lancet Oncol. 2013;14(2):e79–86.CrossRef
15.
Zurück zum Zitat Arenas M, Gomez D, Sabater S, Rovirosa A, Biete A, Colomer J. Decentralisation of radiation therapy. Is it posible and beneficial to patients? Experience of the first 5 years of a satellite radiotherapy unit in the province of Tarragona, Spain. Rep Pract Oncol Radiother. 2014;20(2):141–4.CrossRef Arenas M, Gomez D, Sabater S, Rovirosa A, Biete A, Colomer J. Decentralisation of radiation therapy. Is it posible and beneficial to patients? Experience of the first 5 years of a satellite radiotherapy unit in the province of Tarragona, Spain. Rep Pract Oncol Radiother. 2014;20(2):141–4.CrossRef
16.
Zurück zum Zitat Flynn DF, Hussey DH. Review of the manpower issue in radiation oncology. Int J Radiat Oncol Biol Phys. 1992;24(5):909–12.CrossRef Flynn DF, Hussey DH. Review of the manpower issue in radiation oncology. Int J Radiat Oncol Biol Phys. 1992;24(5):909–12.CrossRef
17.
Zurück zum Zitat Enrici RM, De Sanctis V. Radiation oncology in Italy: the past, the present and the future. Int J Radiat Oncol Biol Phys. 2015;91(4):692–6.CrossRef Enrici RM, De Sanctis V. Radiation oncology in Italy: the past, the present and the future. Int J Radiat Oncol Biol Phys. 2015;91(4):692–6.CrossRef
18.
Zurück zum Zitat Prades J, Algara M, Espinàs JA, Farrús B, Arenas M, Reyes V, et al. Understanding variations in the use of hypofractionated radiotherapy and its specific indications for breast cancer: a mixed-methods study. Radiother Oncol. 2017;123(1):22–8.CrossRef Prades J, Algara M, Espinàs JA, Farrús B, Arenas M, Reyes V, et al. Understanding variations in the use of hypofractionated radiotherapy and its specific indications for breast cancer: a mixed-methods study. Radiother Oncol. 2017;123(1):22–8.CrossRef
19.
Zurück zum Zitat Datta NR, Samiei M, Bodis S. Radiotherapy infrastructure and human resources in Europe—present status and its implications for 2020. Eur J Can. 2014;50:2735–43.CrossRef Datta NR, Samiei M, Bodis S. Radiotherapy infrastructure and human resources in Europe—present status and its implications for 2020. Eur J Can. 2014;50:2735–43.CrossRef
20.
Zurück zum Zitat Pan Hubert Y, Haffty Bruce G, Falit Benjamin P, Buchholz Thomas A, Wilson Lynn D, Hahn Stephen M, et al. Supply and demand for radiation oncology in the United States: updated projections for 2015 to 2025. Int J Radiat Oncol Biol Phys. 2016;96(3):493–500.CrossRef Pan Hubert Y, Haffty Bruce G, Falit Benjamin P, Buchholz Thomas A, Wilson Lynn D, Hahn Stephen M, et al. Supply and demand for radiation oncology in the United States: updated projections for 2015 to 2025. Int J Radiat Oncol Biol Phys. 2016;96(3):493–500.CrossRef
21.
Zurück zum Zitat Stuckless T, Milosevic M, de Metz C, Parliament M, Tompkins B, Brundage M. Managing a national radiation oncologist workforce: a workforce planning model. Radiother Oncol. 2012;103(1):123–9.CrossRef Stuckless T, Milosevic M, de Metz C, Parliament M, Tompkins B, Brundage M. Managing a national radiation oncologist workforce: a workforce planning model. Radiother Oncol. 2012;103(1):123–9.CrossRef
Metadaten
Titel
Are there enough radiation oncologists to lead the new Spanish radiotherapy?
verfasst von
A. Rodríguez
M. Arenas
P. C. Lara
J. López-Torrecilla
M. Algara
A. Conde
H. Pérez-Montero
J. L. Muñoz
P. Peleteiro
M. J. Pérez-Calatayud
J. Contreras
C. Ferrer
The Spanish Society of Oncology and Radiotherapy (SEOR) Analysis Group
Publikationsdatum
03.04.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 12/2019
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02095-x

Weitere Artikel der Ausgabe 12/2019

Clinical and Translational Oncology 12/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.